<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/44CDAA37-A000-4CC6-B623-C2C78D4F916B"><gtr:id>44CDAA37-A000-4CC6-B623-C2C78D4F916B</gtr:id><gtr:name>MRC Virology Unit</gtr:name><gtr:address><gtr:line1>Glasgow University</gtr:line1><gtr:line2>Church Street</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G11 5JR</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/44CDAA37-A000-4CC6-B623-C2C78D4F916B"><gtr:id>44CDAA37-A000-4CC6-B623-C2C78D4F916B</gtr:id><gtr:name>MRC Virology Unit</gtr:name><gtr:address><gtr:line1>Glasgow University</gtr:line1><gtr:line2>Church Street</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G11 5JR</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D"><gtr:id>4E67597F-C9AB-4ED2-BB87-FB1D1FC6FB6D</gtr:id><gtr:name>University of Heidelberg</gtr:name><gtr:address><gtr:line1>University of Heidelberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:postCode>D-69120</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F1AEDFDC-82C6-4623-9593-D806A4E884BE"><gtr:id>F1AEDFDC-82C6-4623-9593-D806A4E884BE</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>McLauchlan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U130184143"><gtr:id>48F80799-7CB2-4576-9CDA-8EBBEA47EE98</gtr:id><gtr:title>Virus-host interactions in hepatitis C virus infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U130184143</gtr:grantReference><gtr:abstractText>At least 250,000 people in the UK are thought to be infected with hepatitis C virus (HCV), which can cause severe liver damage in up to 20 per cent of patients. HCV is much easier to contract than HIV, with prisoners and drug users particularly vulnerable to infection. While there has been considerable progress in the scientific understanding of the disease in recent years, it is extremely difficult to effectively track the spread of HCV and to understand the biological roots of the illness. The lack of surveillance of the disease in the UK has also made it harder for doctors to determine why some patients can develop symptoms as soon as they are infected, while others only go onto develop cirrhosis of the liver after many years. Treatments that can cure patients of infection are available but they are not always successful. By collecting and then analysing clinical samples taken from patients, along with use of laboratory-based methods for studying the virus, the projects in this programme will help us to understand why some people develop disease more rapidly than others and also why certain patients fail to respond to treatment.</gtr:abstractText><gtr:technicalSummary>Chronic hepatitis C virus (HCV) infection causes liver disease, with those developing end-stage liver disease and hepatocellular carcinoma expected to double over the next decade. Whereas HCV infection can be cured in a proportion of patients, the determinants for treatment response are incompletely described. Characterising the complexity of virus/host interactions is essential for a complete understanding of the mechanisms underlying disease progression and treatment response. The programme combines clinical studies on the natural course of HCV infection with fundamental research that enables examination of the virus using in vitro models. Major elements of the programme are:
Patient Cohorts for Clinical and Fundamental Research ? I am principal grant holder for HCV Research UK, a consortium funded by the Medical Research Foundation to recruit 10,000 infected patients from centres across the UK. Funding has established a clinical database and biorepository for research studies into natural infection. We have also created a local cohort, HCV Outcomes, for specific research projects.
Gene Expression Changes in HCV Genotype 1 and 3 Infection - There are 6 HCV genotypes (gts), two of which, gts1 and 3, are the most prevalent in the UK. The pattern of pathogenesis for these genotypes is not identical and they have different responses to pegylated interferon-alpha and ribavirin. Our transcriptomic and microarray studies have found alterations in gene expression between gt1 and gt3 in liver biopsies and PBMCs. This could identify genetic signatures related to disease progression and treatment response. Samples have also been analysed for markers of senescence since T-cell exhaustion occurs during chronic HCV infection. Such an approach aims to link HCV and enhanced biological ageing in infected patients.
The Effect of Infection on the T-cell Receptor Repertoire ? T-cells are crucial for combating HCV. We are developing the technology to explore the T-cell receptor repertoire by high-throughput sequence methods to analyse T-cell populations that temporally change in different population groups (e.g. chronic vs cleared infection) and that recognise specific HCV antigens. These studies will be important for developing possible T-cell based vaccines. 
Development of Systems to Examine HCV Infection - Model systems for studying HCV isolates have been restricted to HCV gts1 and 2 (strain JFH-1). Given the high prevalence of gt3 in the UK, we are creating gt3/gt2 chimeric constructs with the JFH-1 strain. This enables studies on gt3 isolates to examine i) the properties of quasispecies in natural infection, ii) sequences involved in evading intrinsic immune responses and iii) resistance to antiviral therapies.
Host Factors and Processes that Regulate Productive Infection - Host factors and processes are intimately involved in maintaining and regulating HCV infection in vivo. We are conducting studies that examine ISG15, an interferon-regulated factor and the effect of HCV infection on the cell ubiquitinome. For ISG15, our studies examine the mechanism through which ISG15 reduces HCV RNA replication and whether its activity requires ISGylation of cellular or viral substrates. Both cell biology and proteomic approaches are being applied to determine whether HCV infection alters disrtibution of ubiquitinylated proteins and the cell ubiquitinome. Presently, the group has shown that infection induces novel polyubiquitin foci that are being characterised.</gtr:technicalSummary><gtr:fund><gtr:end>2013-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1997-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4051546</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Impact of TRC8 on HCV RNA replication</gtr:description><gtr:id>CFED02F2-242C-47BA-8CD0-84F978752CCD</gtr:id><gtr:impact>As yet there are no publications arising from the collaboration but the preliminary data are potentially exciting and could lead to longer term links with Prof Lehner's group in Cambridge.</gtr:impact><gtr:outcomeId>ARrN1Pj67Z8-1</gtr:outcomeId><gtr:partnerContribution>We have established a collaboration with a group at CIMR in Cambridge who study the role of ubiquitin ligases in virus infection. The link has expanded the range of studies in which we are engaged on interactions between HCV and cellular processes.</gtr:partnerContribution><gtr:piContribution>My group provides the systems for analysis of HCV RNA replication and production of infectious virus.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Arrow Therapeutics</gtr:department><gtr:description>Provision of antibodies</gtr:description><gtr:id>F2DF75E4-D057-45AB-98B2-ADAEA9ED7987</gtr:id><gtr:impact>The company has not divulged any data from their screens.</gtr:impact><gtr:outcomeId>34EB3A86135-1</gtr:outcomeId><gtr:piContribution>The antibodies were unique reagents that were to be used in screening assays to identify unique compounds with anti-HCV activity.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>LipidomicNet Consortium</gtr:description><gtr:id>54C07E23-E35A-4802-AC38-99B1A0B66783</gtr:id><gtr:impact>Inclusion in the consortium has allowed us access to state-of-the-art technology and expert on lipid profiling and cell biology imaging. For the consortium, we add a unique dimension as no other groups studying viruses are part of LipidomicNet.</gtr:impact><gtr:outcomeId>FED35C5C06E-1</gtr:outcomeId><gtr:partnerContribution>Access to facilities for lipid analysis at the Babraham Institute in Cambridge. The institute is also providing back-up by way of training.</gtr:partnerContribution><gtr:piContribution>The consortium is a partnership of about 25 groups from across Europe involved in examining the relationship between human disease and lipid storage. My group is examing this relationship in the context of hepatitis C virus infection.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>Studies on Lipid Metabolism in HCV-Infected Patients</gtr:description><gtr:id>CE8D7EEA-BE5B-4316-A67F-87ED5A60E47F</gtr:id><gtr:impact>The collaboration has given rise to 1 paper (PMID: 20682323).</gtr:impact><gtr:outcomeId>ZnMoea2GkAB-1</gtr:outcomeId><gtr:partnerContribution>Interaction with the group at Newcastle University has enabled us to establish a link with studies on human subjects in the area of lipid metabolism and HCV infection.</gtr:partnerContribution><gtr:piContribution>My group has provided the tissue culture systems that produce infectious HCV to correlate effects of a high fat supplement in natural HCV infection with effects on virus infectivity seen in vitro.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UTMB, Institut Pasteur</gtr:description><gtr:id>18DA63CE-597E-488C-B13B-9335E0D712D2</gtr:id><gtr:impact>The collaboration yielded a publication (PubMed ID 16882659).</gtr:impact><gtr:outcomeId>1222DFB6C46-1</gtr:outcomeId><gtr:partnerContribution>The group at UTMB, along with a group at the Pasteur Institute, provided animals for key parts of a study on GB virus-B, whichis a close genetic relative of HCV.</gtr:partnerContribution><gtr:piContribution>My group produced all of the mutants and performed all of the cell-based analysis for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Institut Pasteur</gtr:description><gtr:id>BB251A0D-E614-40C7-8B22-E0E613570BD4</gtr:id><gtr:impact>This collaboration has led to the publication of 2 papers (PubMed IDs - 18489704, 19269968). It has also facilitated the French group to obtain further funding for their part in the studies.</gtr:impact><gtr:outcomeId>5461FC71499-1</gtr:outcomeId><gtr:partnerContribution>Along with the group at the Pasteur Institute, we have built cell biology studies on certain aspects of HCV infection. The group at Pasteur have not provided us with reagents etc.</gtr:partnerContribution><gtr:piContribution>My group has provided considerable expertise to the group at Pasteur by way of methods in cell biology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heidelberg University</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Heidelberg - Virology</gtr:description><gtr:id>C3C87A60-4580-45A5-8ED7-4BAD0F7BC15A</gtr:id><gtr:impact>The collaboration involved a member of the team from Heidelberg visiting Glasgow to obtain training in biophysical methods. It also led to one publication (PubMed ID 17942391) with others in the process of nearing completion for submission.</gtr:impact><gtr:outcomeId>6D506E4DA08-1</gtr:outcomeId><gtr:partnerContribution>The group at Heidelberg provided key reagents and knowledge that enhanced our programme of work.</gtr:partnerContribution><gtr:piContribution>My group has developed biophysical assays that have given a unique perspective on the properties of HCV proteins. This expertise was incorporated into our collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>C McCormick, University of Southampton</gtr:description><gtr:id>292B7C18-D120-4A3B-B1D7-440804868BAD</gtr:id><gtr:impact>Collaboration has given rise to 1 publication with more in the pipeline. Collaborator also submitted a grant application to MRC (unsuccessful).</gtr:impact><gtr:outcomeId>54639f47615bc3.10500248-1</gtr:outcomeId><gtr:partnerContribution>Partner developed a novel system for examining HCV RNA replication using subgenomic replicons</gtr:partnerContribution><gtr:piContribution>Studies on the mechanism of HCV RNA replication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM U748 (Virus Host Interactions and Liver Diseases)</gtr:department><gtr:description>Collaboration on apoE</gtr:description><gtr:id>6FC440BD-142C-4DF8-B9D0-02AEF6BA725D</gtr:id><gtr:impact>The collaboration resulted in 1 publication [PMID: 20014138].</gtr:impact><gtr:outcomeId>p1LMBVxwgfL-1</gtr:outcomeId><gtr:partnerContribution>The group at Strasbourg broadened our research interests to include studies on the role of apolipoproteins on assembly and release of infectious HCV.</gtr:partnerContribution><gtr:piContribution>My group conducted imaging studies for the collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CC78F486-4408-40CF-8553-E435D845B9C8</gtr:id><gtr:impact>I have given interviews to journalists for newspapers.

There was no further contact with the journalists and so it is difficult to judge any impact.</gtr:impact><gtr:outcomeId>A5708BED90D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>631F518C-E967-4253-9039-8DE511FC28E8</gtr:id><gtr:impact>I have given a presentation to a HepC support group and been involved in fund-raising activities.

Support groups are more aware of the activities funded by MRC to study HCV infection</gtr:impact><gtr:outcomeId>2EE107B3946</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>883A3796-C2DD-477C-9F00-B174E34CFB65</gtr:id><gtr:impact>I have given practical demonstrations and talks at open days for schools.

There are now well-established contacts with local schools and teachers. Students have expressed a greater interest in pursuing a scientific career after the open day events.</gtr:impact><gtr:outcomeId>E2CD1FFEB42</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PCR workshop - Glasgow Science Centre</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D72335E5-64C8-4B9F-AE80-1834C70AE545</gtr:id><gtr:impact>The workshop was organised by Dr D Bhella from the Unit and he will no doubt provide more comprehensive details. Both of the CDFs employed on the project volunteered their time and expertise for the workshop.

As noted above, Dr D Bhella will most likely address this question on behalf of the Unit.</gtr:impact><gtr:outcomeId>1D763298B5F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>126000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Intra-European Fellowship</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>5E6F2928-A005-4AE1-8DED-337B5B708DA5</gtr:id><gtr:outcomeId>834247F1E2C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>327361</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathway Funding Scheme (DPFS)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E3551341-3ACF-4AFA-ABA9-9B5AA0C133E4</gtr:id><gtr:outcomeId>3C1BBE74D770</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>268538</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EC Collaborative Project</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>831AE83E-8037-4679-A23B-62EC89BF7089</gtr:id><gtr:outcomeId>276E33D8FE60</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1924918</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Studies on Liver Disease</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>C0365</gtr:fundingRef><gtr:id>C0C80407-A440-4CED-91F3-6283AA926880</gtr:id><gtr:outcomeId>58bec35c5d6975.97360220</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>My group has produced antibodies, constructs and developed biophysical approaches that have been utilised by a wide number of international groups. Characterisation of the antibodies and constructs has been completed and we continue to develop the biophysical methods. Other researchers are aware of our materials through publication of papers and presentations at conferences. A considerable number of man-years has been devoted to this area and the benefits have been acknowledged in publications from those who have received our materials.</gtr:description><gtr:id>4BA3A96A-C1EA-4E63-9ED6-DFB54C02B667</gtr:id><gtr:impact>Our materials have facilitated the ongoing development of systems for studying HCV biology and also influenced the field related to lipid disorders.</gtr:impact><gtr:outcomeId>809AE2DB593</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HCV materials</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AAF6AFCF-6D6C-4392-AF73-E24CC204D706</gtr:id><gtr:title>Functional characterization of core genes from patients with acute hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b784cfc64594123078dc67f487d27391"><gtr:id>b784cfc64594123078dc67f487d27391</gtr:id><gtr:otherNames>Tang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>gJMNTMBLJuW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE4D389B-BE1E-475B-9BC1-E163075559F3</gtr:id><gtr:title>Increasing rate of cleavage at boundary between non-structural proteins 4B and 5A inhibits replication of hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14590_20_22084249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC9DE504-DC57-4C7C-9BBB-8E4B329477C4</gtr:id><gtr:title>Lipid droplets and hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>8015A8EA39E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F219B29-4D2B-4918-ACF0-92A3989795FE</gtr:id><gtr:title>Hepatitis C virus: assembly and release of virus particles.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>DDWwSfsHzrq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EEC3F56-853F-49C8-9594-532FC1C7BB3F</gtr:id><gtr:title>Lipid metabolism and HCV infection.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_14590_20_21994676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FBA8F51-2BF3-442F-B534-CE3140FF1FA6</gtr:id><gtr:title>The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>9A8FF8B3586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2736594-5665-450C-A943-E06DD5EB4AC5</gtr:id><gtr:title>The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be36d06c89f5a15ffd33bd64c8554099"><gtr:id>be36d06c89f5a15ffd33bd64c8554099</gtr:id><gtr:otherNames>Shavinskaya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>E9A017927DA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>532EA2F6-B192-4F2B-9AD9-411EFDC3C4E8</gtr:id><gtr:title>Signal peptide peptidase cleavage of GB virus B core protein is required for productive infection in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>63F2567F3C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4F08334-7E8C-42CB-A96F-59AA478FF58B</gtr:id><gtr:title>Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f99873305a936fa678a502a79cfe16"><gtr:id>a6f99873305a936fa678a502a79cfe16</gtr:id><gtr:otherNames>Angus AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545a57bea4cee6.96787704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C094CF31-6CB4-4310-A160-3FCDA62404CA</gtr:id><gtr:title>Visualization of double-stranded RNA in cells supporting hepatitis C virus RNA replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8C129472DF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A5425F2-10FE-43BB-9A33-762D3181C359</gtr:id><gtr:title>Mobility analysis of an NS5A-GFP fusion protein in cells actively replicating hepatitis C virus subgenomic RNA.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>10733DF2C4C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D89CF7DD-8DEB-4460-ACBB-D1F37299574E</gtr:id><gtr:title>Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8630b5e1b642f63abe0854dff737976"><gtr:id>e8630b5e1b642f63abe0854dff737976</gtr:id><gtr:otherNames>Roohvand F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>47B57BEF00E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A813A45A-E23A-4ADE-B55E-B4191677ED74</gtr:id><gtr:title>Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>4285C69D23B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC17A857-48C7-445C-A0EE-1BCE392F4FA3</gtr:id><gtr:title>Efficient cleavage by signal peptide peptidase requires residues within the signal peptide between the core and E1 proteins of hepatitis C virus strain J1.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40932adf1e5a3e701095af61f65def52"><gtr:id>40932adf1e5a3e701095af61f65def52</gtr:id><gtr:otherNames>Hope RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>ED66F5A2BFF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE932C49-C0D3-4CD7-AC41-1F07B8493062</gtr:id><gtr:title>Hepatitis C virus: viral proteins on the move.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8c3bb19afe31ed1202a22f36057dcc"><gtr:id>6a8c3bb19afe31ed1202a22f36057dcc</gtr:id><gtr:otherNames>McLauchlan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>E589D32F276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61C9B996-BF9B-414A-875F-3171889407B6</gtr:id><gtr:title>Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>D5A10461BA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21E1DA28-2B55-47C9-A992-72C913DD3795</gtr:id><gtr:title>Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6851dd2a0911ed2113582cb7ab736e"><gtr:id>0b6851dd2a0911ed2113582cb7ab736e</gtr:id><gtr:otherNames>Ratinier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>2D7BE74CD75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B45BC41-E221-4AE1-85D0-AB125FCE055F</gtr:id><gtr:title>Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbbd64fcd1ea78c405e06d38e7028ccc"><gtr:id>dbbd64fcd1ea78c405e06d38e7028ccc</gtr:id><gtr:otherNames>Felmlee DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>iTkx5tPshKq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF734BA-F12D-4A99-BFBD-FB5698B110F0</gtr:id><gtr:title>Maturation of hepatitis C virus core protein by signal peptide peptidase is required for virus production.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52ca551475cb45046074c8ac9c17889d"><gtr:id>52ca551475cb45046074c8ac9c17889d</gtr:id><gtr:otherNames>Targett-Adams P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>FF2898E14C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AB82C00-77FF-4C75-8D6B-8C8079537860</gtr:id><gtr:title>Subcellular localizations of the hepatitis C virus alternate reading frame proteins.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6851dd2a0911ed2113582cb7ab736e"><gtr:id>0b6851dd2a0911ed2113582cb7ab736e</gtr:id><gtr:otherNames>Ratinier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>02BFDB0D004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17A1F5FC-8645-4954-A824-80A8A6FD773D</gtr:id><gtr:title>Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f4d25b6669299e48eaa57afb7ff449e"><gtr:id>4f4d25b6669299e48eaa57afb7ff449e</gtr:id><gtr:otherNames>Jones DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>fCa1VHcw5vz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A83AC2F-2279-4A8F-8F1D-38ADCA116D4D</gtr:id><gtr:title>Determining the cellular diversity of hepatitis C virus quasispecies by single-cell viral sequencing.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb04c8328cd570b159c2b5c170c81045"><gtr:id>bb04c8328cd570b159c2b5c170c81045</gtr:id><gtr:otherNames>McWilliam Leitch EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_14590_20_24049174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>870064F3-C391-404A-9B10-02AA713D9223</gtr:id><gtr:title>Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7824c6b884f13b2d24d23c50b62df18f"><gtr:id>7824c6b884f13b2d24d23c50b62df18f</gtr:id><gtr:otherNames>Benga WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>bjPZXD4DZkq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F948F8A-95DE-44A0-8B97-6D4CA23C6E2D</gtr:id><gtr:title>Non cell autonomous upregulation of CDKN2 transcription linked to progression of chronic hepatitis C disease.</gtr:title><gtr:parentPublicationTitle>Aging cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1ce01119437413e50c82aebe529290"><gtr:id>ff1ce01119437413e50c82aebe529290</gtr:id><gtr:otherNames>Robinson MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-9718</gtr:issn><gtr:outcomeId>pm_14590_20_23931242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38B2A632-53D0-4A1B-B8C7-B6D88B65DEE3</gtr:id><gtr:title>Fluorescence lifetime imaging of alterations to cellular metabolism by domain 2 of the hepatitis C virus core protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a14676baaf8f7a2023c2b9f50efa27d"><gtr:id>6a14676baaf8f7a2023c2b9f50efa27d</gtr:id><gtr:otherNames>Mazumder N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14590_20_23826122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABADC999-A1CF-4CFC-A815-55F3839B45EE</gtr:id><gtr:title>Structural determinants that target the hepatitis C virus core protein to lipid droplets.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1793744db38f8a6171fc453edf6fa11b"><gtr:id>1793744db38f8a6171fc453edf6fa11b</gtr:id><gtr:otherNames>Boulant S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>9EAF68F08D6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U130184143</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>